The study team measured four targeted metabolites using UPLC-MS/MS: creatine riboside, N-acetylneuraminic acid, cortisol sulfate, and a bile-acid glucuronide. They analyzed 4,225 samples—3,875 urine and 350 plasma—from 4,105 individuals drawn from six cohorts. Cases totaled 2,555 samples across eight cancer types; controls numbered 1,670. Breast cancer samples were plasma-only and included two analytes rather than all four.
Samples were collected at or near diagnosis and were assembled in a case-control framework. The authors reported that this sampling approach allowed them to evaluate separation of cases and controls by metabolite signal but also meant that the estimates reflect diagnostic-stage biology rather than pre-diagnostic screening performance.
The study compared eight supervised machine-learning algorithms under cross-validation grouped by individual. The best supervised method was Random forest, which the investigators reported achieved an area under the curve (AUC) of 0.991 (95% CI 0.989–0.993). That performance came from models trained with outcome labels.
To test whether a cancer-associated signal could be detected without using outcome labels at any stage, the team fitted a label-free Gaussian mixture model. That label-free approach produced an AUC of 0.925 (0.917–0.934). The label-free model therefore detected substantial case-control separation even when outcome status was not provided to the algorithm.
Discrimination varied by cancer type. The cohort showed AUCs ranging from 0.996 for mesothelioma down to 0.707 for liver cancer. The authors noted that adjusting for demographic variables changed discrimination only minimally. The article did not report additional model-specific hyperparameters or individual feature importances beyond the overall performance metrics in the abstract; the source did not provide further methodological details in the abstract text.
Within the case group, a higher combined metabolite score was associated with reduced survival. The study team reported a hazard ratio of 1.33 per standard deviation increase in score (95% CI 1.24–1.42). That association indicates that, among diagnosed cases in these cohorts, metabolite elevation correlated with worse prognosis.
The authors translated discrimination to clinical predictive values under an assumed screening prevalence of 0.5%. At that prevalence, the panel produced a positive predictive value of 6.7% and a negative predictive value of 0.999. The high negative predictive value reflects good rule-out performance at very low prevalence; the low positive predictive value indicates that most positive results would be false positives in a general screening population.
The authors were explicit about limitations stemming from study design. Samples were collected at or near diagnosis within a case-control framework; the source stated that these estimates are likely optimistic for screening or pre-diagnostic detection. The report stressed that the low positive predictive value at an assumed population screening prevalence makes the panel unsuitable for population-wide screening in its current form.
The source recommended prospective validation in pre-diagnostic cohorts and in defined high-risk populations. The abstract did not report results from pre-diagnostic samples, nor did it provide prospective performance metrics; therefore, the need for such validation remains an unresolved question documented by the authors. The article also noted technology-transfer arrangements relating to the urinary metabolite assay components, and declared that those arrangements were not active during data collection.
Data availability and oversight were addressed. De-identified individual participant data are available on reasonable request subject to NCI IRB approval and a data-use agreement; analytical code will be deposited on Zenodo upon publication. Ethical approvals were obtained from the Institutional Review Board of the National Cancer Institute and other institutional review boards covering contributing cohorts, and all participants provided written informed consent.
Unanswered questions that remain in the source include how the panel performs in true pre-diagnostic samples, how performance would change when applied prospectively in high-risk groups, and whether calibration or additional markers could raise positive predictive value for screening use. The authors called for those prospective studies as the next step rather than deployment for population screening.